BIOSINO BIO-TEC (08247) plans to acquire a 70.3% stake in Shanghai Jiangcu for approximately 164 million yuan.

BIOSINO BIO-TEC (08247) announced that on August 5, 2026, the company (as an investor) entered into a capital increase and cooperation agreement with the target company Shanghai Jiangcu Technology Co., Ltd., Party B Beijing Chenyi Meng Technology Co., Ltd., and Party D Pan Zhenhe (Parties B and D are original shareholders). The agreement intends to acquire approximately 70.3% of the equity of the target company after capital increase through a combination of shares acquisition and cash capital increase. The total consideration for this transaction is approximately 164 million RMB. Among them, the company will acquire 10% equity of the target company from Party D for a price of 7.7 million RMB, and the company will issue a total of 2,791,250 shares (H shares) to Party D at an issuance price of 3.2 HKD per share according to general authorization as payment; the company will subscribe to the newly increased registered capital of the target company with available cash of about 1.56 billion RMB, thereby acquiring a 67% equity stake in the target company after the capital increase. Upon completion of this transaction, the company will hold approximately 70.3% of the equity in the target company, which will become a non-wholly owned subsidiary of the company, and the financial performance of the target company will be consolidated into the groups financial statements. The target company is primarily engaged in the research and development, sales, and technical services of scientific instruments, biological reagents, IVD fields, as well as upstream core materials, laboratory instruments, and consumables. Its core business includes the authorized distribution of NanoLuc mRNA under Promega in the Chinese region, the academic promotion and distribution of microsatellite instability (MSI) companion diagnostic products for solid tumors, mainly targeting domestic universities, research institutions, medical institutions, and biopharmaceutical companies. It has a certain scale of sales revenue and stable net profits, with its sales pipeline and customer network being highly complementary to the groups IVD business and upstream materials. The Board of Directors believes that this transaction will help broaden the groups distribution channels for industry-academia-research cooperation in IVD products and companion diagnostics for targeted therapies for solid tumors, enhancing market coverage and penetration. It will also help increase the group's profit levels and enhance sustainable profitability while potentially generating synergies with the group's existing business.